Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors

Grant

Date/time Interval

  • May 21, 2019 - May 20, 2024

    • Awarded By

    Total Award Amount

  • 68315.00

    • Direct Costs

  • 52550.00

    • Sponsor Award Id

    • Contributor

  • Alva, Elizabeth   Investigator  
  • Aye, Jamie   Investigator  
  • Friedman M.D., Gregory   Principal Investigator  
  • Johnston, Emily   Investigator  
  • Metrock, Laura   Investigator  
  • Whelan M.D., Kimberly   Investigator